🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Analysis of Biological Characteristics of Advanced ALK-rearranged NSCLC

RecruitingNAAges 18 Years - anyAllGroupe Francais De Pneumo-Cancerologie
NCT05122806 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

BioEXALK is a prospective study evaluating the biological characteristics of advanced ALK-rearranged NSCLC treated with next generation TKIs in first line, included in the national EXPLORE ALK cohort (GFPC 03-2019), a non-interventional, national, multi-center cohort of ALK-rearranged NSCLC patients. BioExALK study will be proposed to every patient included in the Explore ALK GFPC 03-2019 study. Biological analysis will be performed on tumor tissue at diagnosis and at the time of disease progression when available and on circulating tumor DNA (ctDNA). For plasma testing, after obtained patient consent, blood samples will be taken and analyzed at the Léon Bérard Center (Lyon). Biological analysis on tissue obtained at diagnosis and at disease progression will be collected and be sent for centralized analysis to the Rouen University Hospital.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Stage IIIB/IV NSCLC non eligible to locoregional treatment with curative intent * ALK rearrangement confirmed by IHC and/or FISH or NGS according to local methods * Patient included in the EXPLORE ALK study * Age \> or = 18 years * Patient treated with first-line new generation ALKi * Patient agrees to sign an informed consent form and to collect blood samples at inclusion, first tumor evaluation and progression and for whom tumor biopsy at diagnosis is available * Patient enrolled in the french National Health Insurance program or with a third- party payer Exclusion Criteria: * Patients who do not wish to participate in Bioexalk * Patients under guardianship
💊

What it tests

  • RNAseq
📍

Where

46 sites
Pneumologie CHU Félix Guyon
Saint-Denis, France
Centre Hospitalier d'Aix en Provence
Aix-en-Provence, France
Pneumologie CHU
Amiens, France
Centre Hospitalier Universitaire
Angers, France
Centre Hospitalier d'Annecy
Annecy, France
Centre Hospitalier du Morvan
Brest, France
Centre François Baclesse
Caen, France
Pneumologie CH Métropole Savoie
Chambéry, France

…and 38 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy